Sasha Kalcheff-Korn
Executive DirectorRealm of CaringSasha Kalcheff-Korn is the Executive Director of Realm of Caring, a national nonprofit at the forefront of patient education, research, and access to cannabinoid-based care. For the past seven years, she has led the organization at the intersection of public health, emerging medical therapies, and regulatory policy, helping scale Realm of Caring into a trusted resource for tens of thousands of patients, caregivers, and healthcare providers nationwide.
Her work focuses on closing the gap between patient demand and provider readiness in systems shaped by stigma, limited research, and regulatory complexity. Sasha has overseen national observational research in partnership with leading academic institutions, developed clinician education programs, and advocated for evidence-based, compassionate access to care.
Known for translating complex science and policy into actionable insights, she brings a pragmatic, patient-centered perspective to conversations around cannabis, hemp, health equity, and innovation in highly regulated markets.
The Cannabinoid Drug Pipeline: From Clinical Trials to Market
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, s
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the indu
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next.
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next.
You'll learn how to navigate the FDA regulatory pathway, structure clinical trials that withstand scrutiny, and align early-stage research with cannabis business compliance expectations. We'll break down the drug development process stage by stage, then turn to commercialization: pricing, payer access, manufacturing scale, and partnership models that bring a cannabinoid drug to patients.
By the end, you'll leave with a strategic framework for evaluating pipelines, de-risking development, and timing market entry.
